Severe Alcoholic Hepatitis
Conditions
Brief summary
This study aimed to investigate the effect of decontamination by rifaximin in severe alcoholic hepatitis patients. Patients who take corticosteroid or pentoxifylline will be randomly allocated to rifaximin group or control group.
Interventions
DRUGRifaximin
400mg three times per day for 28 days
DRUGCorticosteroid or pentoxifylline
Corticosteroid 40mg/day or pentoxifylline 400mg three times per day for 28 days
Sponsors
Saint Vincent's Hospital, Korea
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
19 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Heavy alcohol drinking within 3 months (Over 40 g/day) * Maddrey's discriminant function ≥ 32 * AST/ALT ration ≥ 2 * Bilirubin level ≥ 5mg/dL * Any one of the following additional criteria : hepatic encephalopathy, enlarged, tender liver, or peripheral leucocytosis * Age : 19-75 * Jaundice within 3 months
Exclusion criteria
* Other causes of chronic liver disease (HBV, HCV, or autoimmune hepatitis) * Antibiotics or probiotics use within 8 weeks * Drug induced hepatotoxicity * Acute viral hepatitis (HAV or HEV) * Hepatic abscess or cholagitis * Hepatocellular carcinoma of modified UICC stage II, III or IV * Malignant tumor other than HCC * Pregnancy * Severe chronic extrahepatic disease * Type I hepatorenal syndrome * Hepatic encephalopathy grade II or IV * Severe infection
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mortality | 6-month |
Contacts
Primary ContactDo Seon Song
Outcome results
None listed